Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial

Annelies Brouwer1,6*, Daniël H. van Raalte2, Michaela Diamant2†, Femke Rutters3, Eus J.W. van Someren4, Frank J. Snoek5, Aartjan T.F. Beekman1 and Marijke A. Bremmer1

Abstract

Background: Major depression and type 2 diabetes often co-occur. Novel treatment strategies for depression in type 2 diabetes patients are warranted, as depression in type 2 diabetes patients is associated with poor prognosis and treatment results. Major depression and concurrent sleep disorders have been related to disturbances of the biological clock. The biological clock is also involved in regulation of glucose metabolism by modulating peripheral insulin sensitivity. Light therapy has been shown to be an effective antidepressant that ‘resets’ the biological clock. We here describe the protocol of a study that evaluates the hypothesis that light therapy improves mood as well as insulin sensitivity in patients with a major depressive episode and type 2 diabetes.

Methods/design: This study is a randomised, double-blind, parallel-arm trial in 98 participants with type 2 diabetes and a major depressive episode, according to DSM-IV criteria. We will assess whether light therapy improves depressive symptoms and insulin sensitivity, our primary outcome measures, and additionally investigate whether these effects are mediated by restoration of the circadian rhythmicity, as measured by sleep and hypothalamic-pituitary-adrenal axis activity. Participants will be randomly allocated to a bright white-yellowish light condition or dim green light condition. Participants will undergo light therapy for half an hour every morning for 4 weeks at home. At several time points, namely before the start of light therapy, during light therapy, after completion of 4 weeks of light therapy and after 4 weeks follow-up, several psychometrical, psychophysiological and glucometabolic measures will be performed.

Discussion: If light therapy effectively improves mood and insulin sensitivity in type 2 diabetes patients with a major depressive episode, light therapy may be a valuable patient friendly addition to the currently available treatment strategies. Additionally, if our data support the role of restoration of circadian rhythmicity, such an observation may guide further development of chronobiological treatment strategies in this patient population.

Trial registration: The Netherlands Trial Register (NTR) NTR4942. Registered 13 January 2015.

*Correspondence: a.brouwer1@vumc.nl
†Deceased
1Department of Psychiatry, EMGO Institute for Health and Care Research, VU University Medical Centre and GGZ inGeest, Amsterdam, The Netherlands
2VU University Medical Centre (ZH4A63), Postal Box 70571007MB, Amsterdam, The Netherlands
Full list of author information is available at the end of the article

© 2015 Brouwer et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Major depression is a mood state characterised by depressed mood and loss of interest or pleasure for at least 2 weeks, together with several other symptoms, such as loss of energy, diminished ability to concentrate, changes in appetite or physical activity and sleep disturbances. Up to 20% of the type 2 diabetes (T2D) patients suffer from major depression [1], where depression appears to be more persistent and recurrent [2–4] and has adverse effects on health behaviour and treatment adherence [5, 6]. Consequently, depression in T2D patients is associated with an increased risk for diabetes complications and mortality [7–16], as well as an economic burden to society [17, 18]. Hence, adequate treatment of depression in T2D patients is required.

Major depression in T2D patients can be treated by psychotherapy or antidepressant drugs. Meta-analytic evidence has shown that antidepressant treatments, both psychological and pharmacological, are only moderately effective in the reduction of depressive symptoms in T2D patients [19, 20]. Glycaemic improvements from anti-depressant therapies have been very modest [20] and some antidepressant drugs have even shown negative metabolic effects, such as weight gain [21] and glucose dysregulation [22]. There clearly is a need for more efficacious treatment strategies of major depression in T2D patients, which improve both psychiatric symptoms and glycaemic control [23].

Light therapy has been shown to be a patient friendly, non-pharmacological antidepressant, which has an early onset of action and a mild adverse-effect profile [24]. Light therapy has been proven successful in patient groups that are traditionally difficult to treat, such as patients with chronic depression and postpartum depression [25–27], and may therefore be effective in the treatment of major depression in T2D patients. Restoration of the circadian rhythmicity, which is often disrupted in depression, has been assumed to be the mechanism of action of light therapy [28]. The biological mechanism behind this chronobiological effect is that light induces the specialised light sensitive retinal ganglion cells to release glutamate in the suprachiasmatic nucleus (SCN) of the brain, which is often called the ‘biological clock’ [29]. The SCN is involved in the regulation of melatonin release, activation of the hypothalamic-pituitary-adrenal (HPA) axis as well as regulation of sleep-wake patterns. A recent clinical study in elderly patients with non-seasonal depression showed that light therapy improved mood, increased upslope evening melatonin levels, attenuated cortisol release and enhanced sleep efficiency [30]. The SCN is also involved in regulation of glucose metabolism [31], which suggests that light therapy may affect glucose metabolism. Two case reports on the effect of light therapy in patients with seasonal depression and insulin dependent diabetes support the idea of effects of light therapy on glucose metabolism [32, 33].

Sleep disturbances, which are indicative of disturbed circadian rhythmicity, often co-occur with major depression [34] and have been associated with hyperglycaemia and increased rates of incident diabetes [35]. In patients with T2D, sleep disorders are associated with a 23% higher fasting glucose level, a 48% increment in fasting insulin levels and a decreased insulin sensitivity as indicated by a 82% increase in homeostatic model assessment of insulin resistance (HOMA-IR) [36, 37]. Two studies using a hyperinsulinaemic-euglycaemic clamp procedure, which is considered the gold standard for the quantification of whole-body insulin sensitivity, observed strong effects of one single night of sleep restriction on insulin sensitivity in healthy volunteers [38] and in patients with type 1 diabetes [39]. Whether the reversed situation, improved insulin sensitivity, can be reached after restoration of the circadian rhythmicity in patients with sleep disturbances has, to the best of our knowledge, not been tested.

We believe that light therapy may be a promising treatment option for patients with major depression and T2D, as light therapy may result in concurrent improvements in depressive symptoms and insulin sensitivity through restoration of the circadian rhythmicity (Fig. 1). To substantiate this theory, we aim to perform a randomised, double-blind, parallel-arm trial that investigates the following hypotheses:

1. Light therapy improves depressive symptoms in patients with a major depressive episode and T2D.
2. Light therapy improves insulin sensitivity in patients with a major depressive episode and T2D.
3. Effects of light therapy on depressive symptoms and insulin sensitivity are mediated by restoration of the circadian rhythmicity, as measured by the sleep-wake pattern and HPA axis activity.

If light therapy proves to be an effective antidepressant in T2D patients and improves insulin sensitivity, light therapy may be a valuable addition to the currently available treatment options for major depression in T2D patients, assuming that improvements in insulin sensitivity may ultimately lead to improvements in glycaemic control.

Methods/design

Design

This study entails a randomised, double-blind, parallel-arm trial, consisting of a run-in period of at least 1 week to allow for study effects, a four-week intervention period and a four-week follow-up period. Assessments of primary and secondary outcome measures, as well as mediating factors, will be performed at baseline, during
the intervention, after the intervention and after the follow-up period to assess direct and long-term effects of light therapy. The trial methods reporting is consistent with the CONSORT statement [40]. A schematic overview of the trial protocol is provided in Fig. 2.

Approval

This study will be executed in accordance with the Helsinki Declaration [41]. Participation in the study is voluntary and written informed consent is obtained. Participants can withdraw their consent to participation at any time, without specification of reasons. The ethical committee of the VU University Medical Centre, Amsterdam, The Netherlands, approved this study.

Participants

Participants will be recruited using a number of strategies: (1) Participants of previous research studies of the VU University Medical Centre will be informed about the study; (2) patients will be informed about the study by affiliated health-care-workers; (3) advertisements in local newspapers, folders and posters in waiting rooms of affiliated health-care-institutions; and (4) via our website. In case patients are interested in participation, a screening consisting of three questions will be applied by telephone. Only patients without a history of laser photocoagulation for the treatment of diabetic retinopathy and scoring 2 or more on one or both questions of the Patient Health Questionnaire-2, a screening tool for a major depressive episode [42], will be invited for a screening visit.

Eligibility for participation will be determined during a screening visit, which constitutes a standardised psychiatric interview, as assessed with the Composite International Diagnostic Interview (CIDI) WHO version 2.1 [43], a medical interview on disease history and medication, physical and blood examination, visual acuity test and fundus photography.

Inclusion criteria

Participants will be included when (1) 18 years or older; (2) having a documented physician-based diagnosis of T2D; and (3) having a major depressive episode according to DSM-IV criteria.
Exclusion criteria

Participants will be excluded from participation when any of the following criteria is present: (1) a recent history of or current use of light therapy; (2) shift worker; (3) a recent change in antidepressant or blood-glucose lowering medication or therapy (e.g. psychotherapy); (4) use of oral glucocorticoids, melatonin, or cytostatics; (5) pregnancy; (6) psychosis, mania, (probable) dementia, severe drug or alcohol abuse, delirium, and severe acute suicidality; (7) a history of light-induced migraine or epilepsy or severe side effects to light therapy in the past; (8) visual acuity <60 %, diabetic retinopathy EURODIAB grades 3, 4 or 5 (severe non-proliferative or prerogative retinopathy, photocoagulated retinopathy, proliferative retinopathy) [44, 45], senile macula degeneration; (9) other medical condition or recent medical event that potentially compromises the effects or safety of light therapy.

There are no restrictions with respect to type of antidepressant or blood-glucose lowering medication.

Safety

Light therapy has proven to be a patient friendly and safe intervention, with little side effects that normally resolve after discontinuation of the therapy.

The ocular safety of light therapy, however, remains matter of debate. Follow-up of patients with cumulative exposure durations up to 1250 h demonstrated that light therapy is safe in patients without pre-existing ocular abnormalities [46]. Ocular effects of light therapy in patients with pre-existing ocular abnormalities, diabetes, or in patients using photosensitising medication, however, remain under speculation [47]. Therefore, stringent ocular exclusion criteria have been defined (e.g. diabetic retinopathy EURODIAB grade 3, 4 and 5) and safety precautions have been taken, such as the use of filters that eliminate an additional part of the energetic light spectrum below 450 nm (blue light), which theoretically has the most damaging potential, in addition to the of UV-A and UV-B filters with which the light therapy lamps are normally equipped (Fig. 3).

Mania (in bipolar depressive patients) and acute suicidality have been theorised as potential psychiatric side effects of light therapy [24, 48, 49] although there is little documented evidence. The investigator will contact a participant weekly during the intervention in order to be able to intervene in case of deterioration of psychiatric symptoms.

**Fig. 3** Light spectral and relative intensity measures. Light spectral and relative intensity measures at 50 cm distance of the bright white-yellowish light condition (yellow), the dim green light condition (green) and the lamp without filter (blue)
**Intervention**

The intervention will consist of light therapy for 30 min every morning, for four consecutive weeks at home. The time at which light therapy is applied in the morning will be determined according to results from the Morningness-Eveningness Questionnaire [24] to allow for accurate phase timing, but in agreement with the participant, to make sure the light therapy can be incorporated in the participant's daily rhythm. A timer will be installed to provide a 90 min time window in which the participants can follow the 30 min of light therapy. This provides the participants with a time window of an hour to start the light therapy, which will prevent participants from taking light therapy at another time of the day. Participants will sit in front of the light boxes at a distance of 50 cm and at an angle of 45 °, while they eat breakfast or do some reading (protocol as recommended by Wirz-Justice and colleagues, 2009 [50]).

Diamond-5 SAD lightbox (CE certified; SAD Lightbox Company, Berkshire, United Kingdom) light therapy lamps will be used. The lamps will be equipped with heat-resistant filters, to create an experimental and placebo light therapy condition.

The experimental condition will be bright white-yellowish light, with an intensity of 10,000 lx at a distance of 50 cm. The lamps will be equipped with high-throughput pale yellow filters (LCT Yellow, Model 212; Lee Filters, Burbank, California, United States of America), to filter the spectrum below 450 nm for ocular safety. The circadian system appears most sensitive to light with short wavelengths and light therapy with light of around 470 nm is able to induce a substantial phase advance [51]. We therefore think filtering for ocular safety will not interfere with our hypothesis. Spectral and intensity measures are depicted in Fig. 3.

The control condition will be dim green light with an intensity of 450 lx at a distance of 50 cm. As the green part of the spectrum around 545 nm is biologically relatively inactive [51], we expect there to be no substantial effects, especially at this low intensity, although expectations will be quite comparable to white light, as was previously shown for dim red light [52]. To create the dim green light condition the lamps will be equipped with low-throughput dark green filters (Aurora Borealis Green: Model 740; Lee Filters, Burbank, California, United States of America). Spectral and intensity measures are depicted in Fig. 3.

**Compliance**

Participants will be instructed by research assistants on how to follow the light therapy program. The position of the light therapy lamp and the participant during light therapy will be marked, so the participant can retake the same position day after day. The investigator will contact the participants weekly during the intervention period and compliance will be monitored and reinforced when needed.

**Randomisation**

Participants will be randomly assigned to the experimental or placebo condition at a 1:1 ratio. Randomisation will be performed in blocks of 6 using a computer-generated table and will be stratified for whether a participant will or will not take part in the hyperinsulinaemic-euglycaemic clamp experiment, which will only be performed in a subgroup of the participants.

**Blinding**

Both investigators and participants will be blind with respect to the treatment conditions. Participants will be informed that two different colours of light (white-yellowish and green) will be compared, but not that a placebo condition is present, nor that the green light is less bright or less effective compared to the white-yellowish lamp. This approach is effective in avoiding differences in participants’ expectations regarding the effectiveness of the conditions, as expectations may affect treatment effects [30, 53, 54]. The investigators involved in data acquisition will be blind to the conditions, as the lamps will be delivered at the participants’ homes by independent research assistants, who are instructed not to discuss the brightness of the lamp, and participants will be instructed not refer any details of their condition to the investigators. A similar blinding procedure showed to be successful in a previous study conducted by our institute [30].

To evaluate the blinding procedure, participants’ expectations of the effect of light therapy on depressive symptoms will be measured before installation of the light therapy lamps, using an adapted version of the expectations questionnaire developed by Lieverse and colleagues, 2011 [30].

**Study setting**

Test visits will be carried out at clinical research units of two locations of the VU University Medical Centre: Amsterdam and Hoorn, The Netherlands.

**Outcome measures**

Outcome measures will be evaluated just before the start of the intervention (T0), after 4 weeks of light therapy (T4) and after 4 weeks of follow-up (T8). Changes in outcome measures (T0 – T4, T4 – T8, or T0 – T8) will be compared between the two study conditions. Additionally, several outcome measures will also be evaluated weekly during the intervention period (T0, T1, T2, T3, T4, T8) to allow for analysis or temporal changes in these measures.
A schematic overview of the outcome measures is depicted in Table 1.

**Participant characteristics**
Various participant characteristics will be obtained before the start of the light therapy (S, T0): psychiatric diagnosis in the category of mood and anxiety disorders according to DSM-IV criteria as assessed using the CIDI WHO version 2.1 [43]; seasonality of depression [55]; chronotype [24]; presence of sleep apnoea [56]; medical history; current medication; biochemical blood tests; and sociodemographic factors. These participant characteristics allow for the characterisation of our study sample.

**Primary outcome measures**
Depressive symptoms will be assessed by the self-report version of the Inventory of Depressive Symptomatology (IDS) (T0, T1, T2, T3, T4, T8) [57]. The IDS allows for profiling of depression, as the questionnaire discriminates directions of the weight, appetite, sleep and psychomotor symptoms, and can be used to determine depression severity. Scores between 14 and 25 indicate mild depression; scores between 26 and 38 indicate moderate depression; scores between 39 and 48 indicate moderate to severe depression; and scores of 49 and greater indicate severe depression. A reduction of 50 % or greater of the baseline depression score is regarded as a clinically significant reduction in depressive symptoms. Depression remission is a priori defined as an IDS score of 13 or less.

Insulin sensitivity will be evaluated at the baseline visit (T0) and the visit following light therapy (T4) in a subsample of 60 participants. Insulin sensitivity will be quantified using a hyperinsulinaemic-euglycaemic clamp procedure, the gold standard for the quantification of whole-body insulin sensitivity. This procedure quantifies the rate of exogenous glucose infusion required to

### Table 1 Outcome measures

| Weeks relative to start intervention (T) | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|----------------------------------------|---|---|---|---|---|---|---|---|---|
| Visits                                 | S | 1 | 2 | 3 |   |   |   |   |   |
| Telephone contact                      |   | 1 | 2 | 3 | 4 |   |   |   |   |
| Run-in phase                           | X-es | X-es |   |   |   |   |   |   |   |
| Intervention phase                     | X-es | X-es | X-es | X-es |   |   |   |   |   |
| Follow-up phase                        | X-es | X-es | X-es | X-es |   |   |   |   |   |
| Participant characteristics            | Psychiatric diagnosis, seasonality, chronotype, sleep apnoea, medical history, current medication, biochemical blood tests, sociodemographic factors | X | X |   |   |   |   |   |   |
| Psychometrical measures                | Depressive symptoms | X | X | X | X | X |   |   | X |
|                                          | Anxiety symptoms | X | X | X | X |   |   |   | X |
|                                          | Diabetes-related distress | X |   |   |   |   |   |   | X |
|                                          | Quality of life, disability | X | X |   |   |   |   |   | X |
| Glucometabolic measures                | Insulin sensitivity | X |   |   |   |   |   |   | X |
|                                          | HbA1c level | X | X |   |   |   |   |   | X |
|                                          | Fasting glucose level | X |   |   |   |   |   |   | X |
|                                          | Hypoglycaemic events | X | X | X | X |   |   |   | X |
| Circadian mediating factors            | Diurnal HPA axis activity | X |   |   |   |   |   |   | X |
|                                          | Objective sleep | X |   |   |   |   |   |   | X |
|                                          | Subjective sleep | X | X | X | X |   |   |   | X |
| Other factors                          | Body weight, body mass index, waist-hip ratio, body composition | X |   |   |   |   |   |   | X |
|                                          | Physical activity | X |   |   |   |   |   |   | X |
|                                          | Autonomic nervous system function | X |   |   |   |   |   |   | X |
| Safety                                  | Adverse effects | X | X | X | X | X |   |   | X |
|                                          | Ophthalmological examination | X |   |   |   |   |   |   | X |
| Compliance                              | Participant-report compliance | X | X | X |   |   |   |   |   |
|                                          | Light meter | X |   |   |   |   |   |   | X |

**Abbreviations:** S screening, HPA hypothalamic-pituitary-adrenal
maintain the plasma glucose concentration at euglycaemic levels in response to a fixed increase in the plasma insulin level. Because 80–90% of the infused glucose is taken up by skeletal muscle under conditions of euglycaemic hyperinsulinaemia, insulin sensitivity measured with this procedure primarily reflects that of skeletal muscle [58]. The hyperinsulinaemic-euglycaemic clamp procedure is performed as previously described by DeFronzo and colleagues [59]. Briefly, participants will be admitted at our research unit following an overnight fast. They are placed in a semi recumbent position during the procedure. A cannula will be inserted into a vein in the antecubital fossa for infusion of glucose and insulin. Insulin (Novorapid 100 IU/ml; Novo Nordisk, Bagsvaerd, Denmark) will be continuously infused at a rate of 40 mU/m2·min, which creates a hyperinsulinaemic state, which will largely decrease endogenous glucose production by the liver. A contralateral dorsal hand or wrist vein will be cannulated and maintained at 50 °C to permit sampling of arterialised venous blood for bedside measurement of blood glucose concentrations (Yellow Springs Instrument 2300 STAT Analyser, Yellow Springs, Ohio, Unites States of America) every 5 min. Glucose (20%) will be infused at a variable rate to maintain blood glucose levels at 5 mmol/L. When a stable blood glucose level of 5 mmol/L is achieved (minimally after 90 min of insulin infusion), the blood glucose level will be kept at this level for 30 min (steady state). At this point the glucose infusion rate equals the skeletal muscle glucose uptake. The M-value (expressed as the amount of glucose infusion in mol/kg·min) will be calculated over this steady state period as described previously [59]. Blood samples for measurement of plasma insulin concentrations will be obtained at several time points before and during insulin infusion.

**Secondary outcome measures**

Secondary participant-reported outcome measures include anxiety symptoms, as anxiety symptoms often co-occur with depressive symptoms; diabetes-related distress; and quality of life and disability, as these measures are increasingly important when evaluating new treatments in clinical trials. Anxiety symptoms are evaluated using the Beck Anxiety Inventory (T0, T1, T2, T3, T4, T8) [60], diabetes-related distress is measured using the Problem Areas In Diabetes questionnaire (T0, T4, T8) [61], quality of life using the EuroQol-5 Dimensions questionnaire (T0, T4, T8) [62] and disability using the Sheehan Disability Scale (T0, T4, T8) [63].

Glucometabolic secondary outcome measures will include the clinically relevant glycated haemoglobin A1c (HbA1c) level (T0, T4, T8), fasting plasma glucose level (T0, T4, T8), and number of hypoglycaemic events as reported in the diary (T0, T1, T2, T3, T4, T8).

**Circadian mediating factors**

Mediating factors that reflect circadian rhythmicity will include diurnal HPA axis activity, objective accelerometer measures of sleep duration and subjective measures of sleep duration and quality.

Diurnal HPA-axis activity is assessed by free cortisol assessment using six saliva samples per day (T0, T4, T8). The morning cortisol awakening responses will be assessed by four saliva samples in the morning: after awakening, plus 30 min, plus 45 min and plus 60 min. Cortisol levels in the evening will be obtained from two saliva samples in the evening at 10 and 11 pm. Saliva samples will be collected at home, using cotton swaps (Salivette, Sarstedt, Nümbrecht, Germany) that will be stored in the refrigerator. Participants will bring the samples with them to the research facility where the saliva will be centrifuged and stored at −80 °C for analysis.

Objective measures of sleep will be obtained using a microelectromechanical system (GENEActiv, Activeinsights Ltd, Kimbolton, United Kingdom), an accelerometer that can reliably measure sleep-wake behaviour [64] and will be worn for one week continuously. Estimates of sleep parameters will be obtained from these data using a previously validated algorithm [64].

Subjective sleep parameters will be scored using the Pittsburg Sleep Quality Index (T0, T4, T8) [65], the Insomnia Severity Index (T0, T2, T4, T8) [66, 67] and a sleep diary (T0, T1, T2, T3, T4, T8) [68].

**Other factors**

Other potential mediating or confounding factors include body weight, body mass index, waist-hip ratio, body composition, physical activity and autonomic nervous system function. Body composition will be measured by bioelectrical impedance analysis (T0, T4, T8) and autonomic nervous system function will be evaluated with spectral analysis of the heart rate variability (T0, T4, T8). Whole blood (T0, T4), plasma and serum (T0, T4, T8) will be collected and stored for future additional research questions that require additional biochemical or DNA analyses.

**Safety and tolerability of light therapy**

Adverse effects of light therapy will be assessed, using a self-report adverse effects questionnaire (T0, T1, T2, T3, T4, T8) that is based on the side effect interview from Lieverse and colleagues, 2011 [30, 69]. The following items will be assessed: tired eyes, dry eyes, painful eyes, visual impairment, headache, early morning awakening, fatigue, drowsiness, weakness, nervousness, anxiety, agitation, irritability, dizziness, nasal congestion, fever, seating, hypoglycaemia, hot flushes, allergy, rash, cough, dry mouth, nausea, vomiting, decreased appetite, increased
appetite, constipation and diarrhoea. Presence and severity of each item will be rated as absent, mild, moderate or severe.

Additionally, we will assess ophthalmological effects, by measures of visual acuity, contrast sensitivity and fundus photography. An ophthalmologist will perform grading of the photographs according to the EURODIAB study grading system [5, 44, 45].

Compliance
Participants will note their compliance to therapy in a diary. Objective measures of compliance will be obtained from lux-meters built in a wrist-worn accelerometer.

Sample size
A previous study on the effects of light therapy on depression in elderly patients using a comparable protocol [30] showed that direct treatment effects of light therapy on depressive symptoms were moderate (effect size 0.50 Cohen’s d), and increased during follow-up (effect size 0.91 Cohen’s d), with one-sided testing. Power calculations were based on the expected moderate effect size and a conservative repeated measures correlation of 0.6, using conventional values for α (0.05) and β (0.20), and two-tailed tests with equal groups – the sample size aimed for will be 42 participants per treatment arm. Accounting for an attrition rate of 15 %, we derive at a total sample size of 98 participants.

The question whether light therapy alters insulin sensitivity in type 2 diabetes patients with depression will be tested in a subsample of 60 participants in total. A sample size of 30 participants per treatment arm is sufficient to detect a moderate effect (0.76 Cohen’s d) of light therapy on insulin sensitivity, with conventional values for α (0.05) and β (0.20), and two-tailed tests with equal groups – the sample size aimed for will be 42 participants per treatment arm. Accounting for an attrition rate of 15 %, we derive at a total sample size of 98 participants.

Sample size aimed for – (0.05) and (0.20), and two-tailed tests with equal groups, as well as participants with diabetic retinopathy EURODIAB grade 3–5 will be excluded from participation in this study as a safety precaution. If our study does find positive effects on mood and insulin sensitivity in absence of ocular damage, it may be worthwhile to investigate the effects of light therapy in patients with diabetic retinopathy EURODIAB.
grade 3–5, as these patients are expected to have a greater risk for depression and poor glycaemic control.

Conclusions
If light therapy shows to be safe and effective in the reduction of depressive symptoms and improves insulin sensitivity, light therapy may be a valuable patient friendly addition to the currently available treatment strategies for major depression in T2D patients, assuming that improved insulin sensitivity may lead to improvements in glycaemic control, as measured by fasting glucose levels and HbA1c levels. Additionally, if our data support the role of restoration of circadian rhythm in these effects, such a finding may guide further development of chronobiological treatment strategies in these patients, as well as provide a basis for research into the effects of light therapy in other T2D patients, such as those without major depression but with sleep disorders.

Trial status
The first participant was enrolled in June 2014. At the time of submission of this study protocol participants were still being recruited.

Abbreviations
IDS: Inventory of depressive symptomatology; CIDI: Composite International Diagnostic Interview; HbA1c: glycated haemoglobin A1c; HPA: Hypothalamic-pituitary-adrenal; SCN: Suprachiasmatic nucleus; T2D: Type 2 diabetes.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AB is trial coordinator, participated in the study design and participant recruitment, and drafted the manuscript. MAB conceived the study, set up the preliminary study design, is the principal investigator of this study and helped to draft this manuscript. DHR and MD participated in the somatic design of the study. FR participated in the participant recruitment. EJWS participated in the trial conditions and sleep measures design. FJS and ATF helped conceive the study and participated in the study design and participant recruitment. All authors except MD (deceased) read, edited and approved the final manuscript.

Authors’ information
AB is a research physician. MAB is psychiatrist and post-doctoral researcher. DHR is internal medicine resident and post-doctoral researcher. MD (deceased) was professor of diabetology. FR is an epidemiologist and post-doctoral researcher. EJWS is professor of psychophysiology. FJS is psychologist and professor of medical psychology. ATF is psychiatrist and professor of psychiatry.

Acknowledgements
This study is supported by a European Foundation for the Study of Diabetes (EFSDF)+Lilly Mental Health award. The authors wish to acknowledge clinical scientist John H. G. M. Klaessens for assessing the light spectrum and relative intensity measures of the light therapy conditions.

Author details
1Department of Psychiatry, EMGO Institute for Health and Care Research, VU University Medical Centre and GGZ inGeest, Amsterdam, The Netherlands. 2Departments of Integrative Neurophysiology and Medical Psychology, Centre for Neurogenomics and Cognitive Research (CNCR), Neuroscience Campus Amsterdam, VU University and Medical Centre, Amsterdam, The Netherlands. 3Department of Medical Psychology, VU University Medical Centre, Amsterdam, The Netherlands. 4Department of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands. 5Departments of Integrative Neurophysiology and Medical Psychology, Centre for Neurogenomics and Cognitive Research (CNCR), Neuroscience Campus Amsterdam, VU University and Medical Centre, Amsterdam, The Netherlands. 6Department of Medical Psychology, VU University Medical Centre, Amsterdam, The Netherlands. 7Department of Medical Psychology, VU University Medical Centre, Amsterdam, The Netherlands. 8University Medical Centre, Amsterdam, The Netherlands.

Received: 13 April 2015 Accepted: 25 June 2015

Published online: 24 July 2015

References
1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.
2. Lustman PJ, Griffith LS, Clouse RE. Depression in adults with diabetes. Results of 5-years follow-up study. Diabetes Care. 1988;11:605–12.
3. Lustman PJ, Griffith LS, Freedland KE, Clouse RE. The course of major depression in diabetes. Gen Hosp Psychiatry. 1997;19:138–43.
4. Peyrot M, Rubin RR. Persistence of depressive symptoms in diabetic adults. Diabetes Care. 1999;22:448–52.
5. Gonzalez JS, Peyrot M, McClar LA, Collins EM, Serpa L, Mimiga MJ, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31:1298–303.
6. Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27:2154–60.
7. Katon WJ, Lin EH, Williams LH, Ciechanowski P, Heckbert SR, Ludman E, et al. Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study. J Gen Intern Med. 2010;25:423–9.
8. Lin EH, Heckbert SR, Clouse RE, Katon WJ, Ciechanowski P, Ludman EJ, et al. Depression and increased mortality in diabetes: unexpected causes of death. Ann Fam Med. 2009;7:414–21.
9. Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care. 2010;33:264–9.
10. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30.
11. Zhang X, Norris SL, Gregg EW, Cheng YJ, Beckles G, Kahn HS. Depressive symptoms and mortality among persons with and without diabetes. Am J Epidemiol. 2005;161:652–60.
12. Clouse RE, Lustman PJ, Freedland KE, Griffith LS, McGill JB, Carney RM. Depression and coronary heart disease in women with diabetes. Psychosom Med. 2003;65:576–83.
13. Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis. 2000;148:159–69.
14. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996;16:203–6.
15. Williams LH, Rutter CM, Katon WJ, Reiber GE, Ciechanowski P, Heckbert SR, et al. Depression and incident diabetic foot ulcers: a prospective cohort study. Am J Med. 2010;123:748–54.
16. Sieu N, Katon W, Lin EH, Russo J, Ludman E, Ciechanowski P. Depression and incident diabetic retinopathy: a prospective cohort study. Gen Hosp Psychiatry. 2011;33:429–35.
17. Finkelstein EA, Bray JW, Chen H, Larson MJ, Miller K, Tompkins C, et al. Prevalence and costs of major depression among elderly claimants with diabetes. Diabetes Care. 2003;26:415–20.
18. Greden JF. The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry. 2001;62 Suppl. 225–9.
19. van der Feltz-Cornelis CM, Nuyen J, Stoop C, Chan J, Jacobson AM, Katon W, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2010;32:380–95.
20. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database Syst Rev. 2012;12:CD008381.
21. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61 Suppl 11:37–41.
22. Deuchs M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry. 2013;26:60–5.
23. Katon W. Depression and diabetes: unhealthy bedfellows. Depress Anxiety. 2010;27:323–6.
24. Terman M, Terman JS. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectr. 2005;10:647–63.
25. Remmersma-van der Lek RF, Swaaf DF, Tvisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299:2642–55.
26. Goel N, Terman M, Terman JS, Macchi MM, Stewart JW. Controlled trial of bright light and negative air ions for chronic depression. Psychol Med. 2005;35:945–55.
27. Epperson CN, Terman M, Terman JS, Hanusa BH, Oren DA, Peindl KS, et al. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. J Clin Psychiatry. 2004;65:421–5.
28. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol. 2006;21 Suppl 1:1–5.
29. Reghunandanan V, Kripke DF, Elliott JA, Knickerbocker NC, Gandriner MA. Bright light treatment for depression of older adults [ISRCTN55452501]. BMC Psychiatry. 2005;5:41.
30. Leuchter AF, Hunter AM, Tartter M, Cook IA. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014;205:443–9.
31. Knappen SE, van de Venken W, Gondijn MC, Meesters Y. The duration of light therapy and treatment outcome in seasonal affective disorder. J Affect Disord. 2014;166:433–6.
32. Mersch PP, Vastenburg NC, Meesters Y, Bouhuys AL, Beens GM, van den Hoofddakker RH, et al. The reliability and validity of the Seasonal Pattern Assessment Questionnaire: a comparison between patient groups. J Affect Disord. 2004;80:209–19.
33. Netzer NC, Strohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Am Intern Med. 1999;131:485–9.
34. Rush AJ, Gallin PF, Lack LC. Clinical syndromes: differential effects of light wavelength in phase advancing the melatonin rhythm. J Pineal Res. 2004;36:140–4.
35. Rush AJ, Gallin PF, Lack LC, Kripke DF. Differential effects of light wavelength in phase advancing the melatonin rhythm. J Pineal Res. 2004;36:140–4.
36. Konerding U, Elkhuisen SG, Faubel R, Forte P, Malmstrom T, Pavi E, et al. The efficacy, protocol, safety, and side effects of light therapy for depression in elderly patients [ISRCTN55452501]. BMC Psychiatry. 2005;5:41.
37. Netzer NC, Strohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Am Intern Med. 1999;131:485–9.
38. Rush AJ, Gallin PF, Lack LC. Clinical syndromes: differential effects of light wavelength in phase advancing the melatonin rhythm. J Pineal Res. 2004;36:140–4.
39. Rush AJ, Gallin PF, Lack LC, Kripke DF. Differential effects of light wavelength in phase advancing the melatonin rhythm. J Pineal Res. 2004;36:140–4.
40. Loving RT, Kripke DF, Elliott JA, Knickerbocker NC, Gandriner MA. Bright light treatment for depression of older adults [ISRCTN55452501]. BMC Psychiatry. 2005;5:41.
41. Leuchter AF, Hunter AM, Tartter M, Cook IA. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014;205:443–9.
42. Konerding U, Elkhuisen SG, Faubel R, Forte P, Malmstrom T, Pavi E, et al. The validity of the EQ-SD-3L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014;12:81.
43. Leon AC, Offson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:935–105.
44. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:157–63.
45. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E212–23.
46. Less need for insulin, a surprising effect of phototherapy in insulin-dependent diabetes mellitus. Tijdschr Psychiatr. 2009;51:975–7.
47. Terman M, Terman JS. Bright light therapy: side effects and benefits across the symptom spectrum. J Clin Psychiatry. 1999;60:799–808.
48. Praschak-Rieder N, Neumeister A, Hesselmann B, Veltier M, Bams C, Saper C. Suicidal tendencies as a complication of light therapy for seasonal affective disorder: a report of three cases. J Clin Psychiatry. 1997;58:389–92.
49. Wirz-Justice A, Benedetti F, Terman M. Chronotherapeutics for Affective Disorders: A Clinician's Manual for Light and Wake Therapy. 2nd ed. Basel: Karger Medical and Scientific Publishers; 2009.
50. Wright HR, Lack LC, Kripke DF. Differential effects of light wavelength in phase advancing the melatonin rhythm. J Pineal Res. 2004;36:140–4.
51. Loving RT, Kripke DF, Elliott JA, Knickerbocker NC, Gandriner MA. Bright light treatment for depression of older adults [ISRCTN55452501]. BMC Psychiatry. 2005;5:41.
52. Loving RT, Kripke DF, Elliott JA, Knickerbocker NC, Gandriner MA. Bright light treatment for depression of older adults [ISRCTN55452501]. BMC Psychiatry. 2005;5:41.
53. Konerding U, Elkhuisen SG, Faubel R, Forte P, Malmstrom T, Pavi E, et al. The validity of the EQ-SD-3L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014;12:81.